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Abstract 
This dissertation includes two papers with each distributed in one chapter.  
To date, genome-wide association studies (GWAS) have identified a large number of 
common variants that are associated with complex diseases successfully. However, the 
common variants identified by GWAS only account for a small proportion of trait 
heritability. Many studies showed that rare variants could explain parts of the missing 
heritability. Since the well-developed common variant detecting methods are 
underpowered for rare variant association tests unless sample sizes or effect sizes are very 
large, investigation the roles of rare variants in complex diseases presents substantial 
challenges. In chapter 1, we proposed novel statistical tests to test the association between 
rare and common variants in a genomic region and a complex trait of interest based on 
cross-validation prediction error. we first proposed a prediction error method (PE) based 
on Ridge regression. Based on PE, we also proposed another two tests PE-WS and PE-
TOW by testing a weighted combination of variants with two different weighting 
schemes. Using extensive simulation studies, we showed that PE-TOW and PE-WS are 
consistently more powerful than TOW and WS, respectively, and PE is the most powerful 
test when causal variants contain both common and rare variants. 
In genome-wide association studies (GWAS), the joint analysis of multiple phenotypes 
could have increased power over analyzing each phenotype individually. With this 
motivation, several methods that jointly analyze multiple phenotypes have been 
developed, such as O’Brien’s method, Trait-based Association Test that uses Extended 
x 
Simes procedure (TATES), MAONVA and MultiPhen. However, the performance of 
these methods under a wide range of scenarios is not consistent: one test may be powerful 
in some situations, but not in the others. Thus, one challenge in joint analysis of multiple 
phenotypes is to construct a test that could maintain good performance across different 
scenarios. In chapter 2, we developed a novel statistical method to test the association 
between a genetic variant and multiple phenotypes based on cross-validation prediction 
error. Extensive simulations were conducted to evaluate the type I error rates and to 
compare the power performance of the PE method with various existing methods. 
Simulation studies showed that the PE method controls the type I error rates very well 
and has consistently higher power than the tests we compared in all the scenarios.  
1 
 
1 Chapter 1 
Detecting Association of Rare and Common Variants based on Cross-Validation 
Prediction Error 
Despite the extensive discovery of disease-associated common variants, much of the 
genetic contribution to complex traits remains unexplained. Rare variants may explain 
additional disease risk or trait variability. Although sequencing technology provides a 
supreme opportunity to investigate the roles of rare variants in complex diseases, 
detection of these variants in sequencing-based association studies presents substantial 
challenges. In this article, we propose novel statistical tests to test the association between 
rare and common variants in a genomic region and a complex trait of interest based on 
cross-validation prediction error. We first propose a prediction error method (PE) based 
on Ridge regression. Based on PE, we also propose another two tests PE-WS and PE-
TOW by testing a weighted combination of variants with two different weighting 
schemes. PE-WS is the prediction error version of the test based on the weighted sum 
statistic (WS) and PE-TOW is the prediction error version of the test based on the 
optimally weighted combination of variants (TOW). Using extensive simulation studies, 
we are able to show that (1) PE-TOW and PE-WS are consistently more powerful than 
TOW and WS, respectively, and (2) PE is the most powerful test when causal variants 
contain both common and rare variants. 
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1.1 Introduction 
The main purpose of genome-wide association studies (GWAS) is to detect common 
variants by indirect mapping methods. GWAS have identified a large number of common 
variants that are associated with complex diseases successfully [Bodmer and Bonilla, 
2008; Lango Allen et al., 2010; Ng et al., 2009; Pritchard, 2001; Pritchard and Cox, 2002; 
Stratton and Rahman, 2008; Teer and Mullikin, 2010; Walsh and King, 2007]. However, 
the common variants identified by GWAS only account for a small fraction of trait 
heritability [McCarthy et al., 2008], parts of the missing heritability could be caused by 
rare variants [Cohen et al., 2006; Ji et al., 2008; Manolio et al., 2009; Marini et al., 2008; 
Zhu et al., 2010]. In rare variant association studies, instead of indirect association 
mapping method, all rare variants need to be tested directly. The new sequencing 
technology allows sequencing of exome-wide and whole-genome of a large amount of 
individuals [Hodges et al., 2007], which makes directly test for rare variants possible 
[Andre’s et al., 2007]. Current exome-wide and whole-genome sequencing studies have 
successfully detected many rare variants responsible for many complex traits, such as 
LDL Cholesterol [Lange et al., 2014], bone mineral density [Huang et al., 2015], thyroid 
function [Zheng et al., 2015], circulating lipid levels [Taylor et al., 2015], and other traits 
[Walter et al., 2015].  
There is an increasing number of researchers who are interested in rare variants 
association studies [Cohen et al., 2004; Ji et al., 2008; Ahituv et al., 2007; Romeo et al., 
2007; Romeo et al., 2009]. Since the well-developed common variant detecting methods 
3 
 
are underpowered for rare variant association tests unless sample sizes or effect sizes are 
very large, several new methods for rare variant association studies are proposed recently. 
These methods include burden tests, quadratic tests, and robust tests. Burden tests include 
the cohort allelic sums test (CAST) [Morgenthaler and Thilly, 2007], the combined 
multivariate and collapsing (CMC) method [Li and Leal, 2008], the weighted sum 
statistic (WS) [Madsen and Browning, 2009], and variable threshold (VT) method [Price 
et al., 2010]. Burden tests collapse rare variants in a genomic region into a single burden 
variable and then regress the phenotype on the burden variable to test for the cumulative 
effects of rare variants in the region [Lee et al., 2012]. These tests implicitly assume that 
all rare variants are causal and that the directions of the effects are all the same. Quadratic 
tests include tests with statistics of quadratic forms of the score vector such as the 
sequence kernel association test (SKAT) [Wu et al., 2011], the sequence kernel 
association test for the combined effect of rare and common variants (SKAT-C) [Ionita-
Laza et al., 2013], the test for optimally weighted combination of variants (TOW) [Sha 
et al., 2012], as well as adaptive weighting methods such as data-adaptive sum (aSUM) 
[Han and Pan, 2010], adaptive weighting (AW) methods [Sha et al., 2013], and methods 
proposed by Hoffmann et al. [2010], Lin and Tang [2011], and Yi and Zhi [2011]. 
Quadratic tests are robust to the directions of the effects of causal variants and are less 
affected by neutral variants than burden tests. Burden tests can only outperform quadratic 
tests when most of rare variants are causal and the directions of the effects of causal 
variants are all the same. Robust tests include methods proposed by Derkach et al. [2012], 
Lee et al. [2012], Greco et al. [2016], and Sha and Zhang [2014]. Robust tests combine 
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information from burden tests, quadratic tests, and possibly other tests aiming to have 
advantages of burden, quadratic, and possibly other tests. 
In this paper, we develop novel statistical methods to test the association between 
common and rare variants in a genomic region and a complex trait of interest based on 
cross-validation prediction error. We first propose a prediction error method (PE) based 
on Ridge regression. Based on PE, we also propose another two tests PE-WS and PE-
TOW by testing a weighted combination of variants with two different weighting 
schemes, the weights suggested by Madsen and Browning [2009] and the optimal 
weighting scheme developed by Sha et al. [2012]. By extensive simulation studies, we 
show that (1) the prediction error versions of TOW and WS (PE-TOW and PE-WS) are 
consistently more powerful than TOW and WS, respectively, and (2) PE is the most 
powerful test when the causal variants contain both common and rare variants. 
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1.2 Method 
Prediction Error Model 
Consider a sample of n  unrelated individuals. Each individual has been genotyped at M  
variants in a genomic region. Denote iy  as the value of a quantitative trait of the thi  
individual and denote 1( ,..., )
T
i i iMg g g=  as the genotypic scores of the 
thi  individual at 
M  variants, where {0,  1,  2}img ∈  is the number of minor alleles the thi  individual has 
at the thm  variant. We assume that there are no covariates. If there are p  covariates, 
1 ,,i ipz z… , for the 
thi  individual, we adjust genotypes and trait values for the covariates 
using the method applied by Price et al. [2006] and Sha et al. [2012], that is, adjusting 
both genotypes and trait values for the covariates through linear models  
0 1 1 ...i i p ip iy z zα α α ε= + + + +  and 0 1 1 ...im m m i pm ip img z zα α α τ= + + + + .  
Our working model is 
0 11 i M iMi iy g gβ εβ β= + + + + .                                                (1) 
To test association under our working model (1), we test the null hypothesis 
10 : 0MH ββ = = = . 
In the k-fold cross-validation, we divide the data into k equal parts, then use each of the 
k parts as the testing set and the other k-1 parts as the training set. We use the training set 
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to estimate ( )0 , ,
T
Mβ β β= …  in equation (1), and use the prediction equation 
0 11
ˆ ˆ ˆˆi i MM ig gy β β β+ += +  to predict the trait values in the testing set. Since the 
genotype data of rare variants are sparse, the smaller the training set is, the more likely 
the problem of singular of the design matrix will be. Thus, we should try to use the 
training set as large as possible. In the k-fold cross-validation, the leave-one-out cross-
validation (LOOCV) (k equals n) gives the largest training sets. Furthermore, the LOOCV 
prediction error has a closed-form formula [James et al., 2013] (also see Appendix A for 
0λ = ). Therefore, our proposed tests are based on LOOCV.  
In this paper, we construct a novel statistical test to test the association between genotypes 
of common and rare variants in a genomic region and a complex trait of interest based on 
the LOOCV prediction error. We propose to use the LOOCV prediction error under 
model (1) as a test statistic. Let ˆciy  denote the LOOCV predicted value of iy  under model 
(1). Then, the statistic can be written as  
 ( )2
1
ˆ
n
i ci
i
T y y
=
= −∑ .                                                (2) 
Note that T  is the LOOCV prediction error. Thus, low values of T  would imply 
significance. 
Ridge regression 
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For rare variants, one drawback of the aforementioned LOOCV procedure is that some 
columns of the design matrix may have all zeros, if we leave one individual out. When 
the design matrix is not full rank or columns of the design matrix are highly correlated, 
we can use penalized regressions, such as Ridge regression [Halawa and Bassiouni, 2000; 
Hoerl et al., 1975] and Lasso regression [Yuan and Lin, 2006; Meier et al., 2008; 
Tibshirani, 1996] among others. Penalized regressions have been applied to the analysis 
of genetic data [Cule et al., 2011; Warren et al., 2014; Ayers and Cordell, 2013; Ayers 
and Cordell, 2010; Cule and De Iorio, 2013; Malo et al., 2008]. In this paper, we propose 
to use Ridge regression. Ridge regression penalizes the size of the regression coefficients. 
Let 1(1, ,..., )
T
i i iMx g g=  and ( )0 , ,
T
Mβ β β= … . In the regression model 
,  1,2,...,i
T
i iy x i nβ ε= + = , the Ridge regression estimator βˆ  is defined as the value of β  
that minimizes 2 2( )Ti i j
i j
y x β λ β− +∑ ∑ , where 0λ ≥  is a tuning parameter. The solution 
to the Ridge regression is given by 1ˆ ( )T TX X I X yβ λ −= + , where ( )1, , n
TX x x…= . The 
LOOCV prediction error for Ridge regression also has a closed-form formula (see 
Appendix A). For Ridge regression, we denote the test statistic given by equation (2) as 
Tλ . Let pλ  denote the p-value of Tλ , where pλ  is evaluated using equation (4) in the 
next section and ( )0p pλ λ= . We define the LOOCV Prediction Error test statistic (PE) as  
                                minPET pλ λ= .                                                   (3)  
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In this study, we use a simple method to evaluate the minimization. We divide the interval 
[0, )∞ into subintervals 1 10 ... K Kλ λ λ−< < <≤ < ∞ . In the simulation studies (see later), 
we used 10K =  and ( ) ( )1 10log , log 1,, ,10λ λ… …= . Then, 1min min kPE k KT p pλ λ λ≤ ≤= =
.   
We use a permutation procedure to evaluate the p-value of PET . Intuitively, two layers of 
permutations are needed to estimate 
k
pλ  and the overall p-value for the test statistic PET
. Ge et al. [2003] proposed that one layer of permutation can be used to estimate 
k
pλ  and 
the overall p-value for the test statistic PET . Here, we use the permutation procedure of 
Ge et al. to estimate 
k
pλ  and the overall p-value for the test statistic PET . In each 
permutation, we randomly shuffle the trait values. Suppose that we perform B  replicates 
of permutations. Let ( )
k
bTλ  denote the values of kTλ  based on the 
thb  permuted data for 
0,1,...,b B=  and , ,1k K= … , where 0b =  represents the original data. Then, we transfer 
( )
k
bTλ  to 
( )
k
bpλ  by  
( )
( ) ( )
( ) : 1, }#{  for ,k k
k
d b
b dp
f b
d T T Bλ λ
λ
…< =
= ,                                 (4) 
where ( )0f B=  and ( ) 1f b B= −  for , ,1b B= … . Let ( ) ( )1min k
b b
k Kp pλ≤ ≤= . Then, the p-
value of PET  is given by  
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( ) (0)#{ :  for 1,2, , }bb p bp B
B
= …< . 
See Appendix B for a fast algorithm for the permutation procedure. 
For testing the effects of common and rare variants, we also propose the following two 
methods based on the framework of PE. These two methods are to test the effect of a 
weighted combination of variants with two different weighting schemes: 
1. Weighted sum weighting scheme: in this weighting scheme, we replace 
1( ,..., )
T
i i iMg g g=  with 
1
M
i m im
m
G w g
=
=∑ , where ( )
1
1m m
mw
p p
=
−
 is the weight 
suggested by Madsen and Browning [2009] and mp  is the minor allele frequency 
of the thm  variant. The test statistic given by equation (3) based on this weighting 
scheme is called weighted sum method based on prediction error (PE-WS). 
 
2. Optimal weighting scheme: in this weighting scheme, we replace 
1( ,..., )
T
i i iMg g g=  with 
1
M
i m im
m
G w g
=
=∑ , where 
( )( )
1
2
1
( )
n
mi im
i
n
i
m
m m
i
g
g
y y g
w
g
=
=
− −
=
−
∑
∑
 is the 
weight suggested by Sha et al. [2012]. The test statistic given by equation (3) 
based on this weighting scheme is called testing an optimally weighted 
combination of variants based on prediction error (PE-TOW). 
10 
 
We use the same permutation procedure as PE to evaluate the p-values of PE-WS and 
PE-TOW. See Appendix B for fast algorithms for the permutation procedures of PE-WS 
and PE-TOW. 
Comparison of Tests  
We compare the performance of the three proposed tests, PE, PE-WS, and PE-TOW, with 
that of the weighted sum statistic (WS) [Madsen and Browning, 2009], the sequence 
kernel association test (SKAT) [Wu et al., 2011], the sequence kernel association test for 
the combined effect of rare and common variants (SKAT-C) [Ionita-Laza et al., 2013], 
and the test for the optimally weighted combination of variants (TOW) [Sha et al., 2012].  
  
11 
 
1.3 Simulation Study 
In simulation studies, we generate genotype data using the Genetic Analysis Workshop 
17 (GAW17) data. This dataset contains genotypes of 697 unrelated individuals on 3205 
genes. Similar to Sha et al. [2012], we choose four genes: ELAVL4, MSH4, PDE4B, and 
ADAMTS4 with 10, 20, 30, and 40 variants, respectively, and then merge the four genes 
to form a super gene (Sgene) with 100 variants. We generate genotypes based on the 
genotypes of 697 individuals in the Sgene.  
To evaluate type I error, we generate trait values independent of genotypes by using the 
model:  
1 20.5 0.5y Z Z ε= + +                                              (5) 
where 1Z  is a continuous covariate generated from a standard normal distribution, 2Z  is 
a binary covariate taking values 0 and 1 with a probability of 0.5, and ε  follows a 
standard normal distribution. 
To evaluate power, we randomly choose cn  rare variants and one common variant as 
causal variants and assume that all the cn  rare causal variants have the same heritability. 
rn  and pn  are the number of risk rare variants and protective rare variants, respectively, 
then r p cn n n+ = . Denote 
r
ix , pjx , and cx  as the genotypes of the thi  risk rare variant, the 
12 
 
thj  protective rare variant, and the common causal variant, respectively. Then, we 
generate a quantitative trait by the following model: 
1 1
1 20.5 0.5
pr nn
r r p p
i i j
i
c
j
cjy Z Z x x xβ β β ε
= =
= + + − + +∑ ∑                                   (6) 
where 1Z , 2Z  and ε  are the same as those in equation (5). In equation (6), 
r
iβ , 
p
jβ  and 
cβ  are constant coefficients. The values of 
r
iβ , 
p
jβ  and cβ  depend on the total 
heritability totalh  and the ratio of the heritability of rare causal variants to the heritability 
of the common causal variant R . For given totalh  and R , based on equation (6), we can 
calculate the heritability of the rare casual variants and the heritability of the common 
causal variant. From the heritability of the common causal variant, we can calculate cβ . 
From the heritability of the rare casual variants and the assumption that all the rare causal 
variants have the same heritability, we can calculate the heritability of each rare causal 
variant. Then, we can calculate riβ  and 
p
jβ . The formulae to calculate the values of 
r
iβ , 
p
jβ  and cβ  are given by ( ) ( )( )var 1 1
r total
i r
i c total
h R
x n h R
β
−
=
+
, 
( ) ( )( )var 1 1
p total
p
j
j
c total
h R
x n h R
β = −
− +
, and 
( ) ( ) ( )var 1 1
total
c to l
c
ta
h
x h R
β =
− +
, respectively. 
For power comparisons, we consider two different cases: (1) “Rare” in which all causal 
variants are rare (minor allele frequency < 0.01) and (2) “Both” in which both rare and 
common variants contribute to the trait. In each case, we consider two subcases: with 
13 
 
covariates and without covariates. In the subcase of without covariates, 1Z , 2Z  are not 
included in equation (6). 
1.4 Simulation Results 
For evaluating the Type I error of the proposed methods (PE, PE-TOW and PW-WS), we 
consider different disease models (with or without covariates), different significance 
levels, and different sample sizes. The p-values are calculated using 10,000 permutations. 
Type I error rates are evaluated using 10,000 replicated samples. For 10,000 replicated 
samples, the 95% confidence intervals (CIs) for the estimated type I error rates of nominal 
levels 0.05, 0.01, and 0.001 are (0.046, 0.054), (0.008, 0.012), and (0.00038, 0.00162), 
respectively. The estimated type I error rates of the three proposed tests are summarized 
in Table 1. From this table, we can see that most of the estimated type I error rates are 
within 95% CIs and those type I error rates not within the 95% CIs are very close to the 
bound of the corresponding 95% CI, which indicates that the proposed methods are valid. 
In power comparisons, the p-values of PE, PE-TOW, PE-WS, and TOW are calculated 
using 1,000 permutations, while the p-values of WS, SKAT, and SKAT-C are calculated 
by asymptotic distributions. The powers of all of the seven tests are evaluated using 1,000 
replicated samples at a significance level of 0.05 (Figures 1-3). For Figure 4, the powers 
of all of the seven tests are evaluated using 1,000 replicated samples at a significance 
level of 10-6 and p-values of PE-WS, PE-TOW, PE and TOW are evaluated by 107 
permutations.  
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Power comparisons of the seven tests (PE, PE-TOW, TOW, PE-WS, WS, SKAT, and 
SKAT-C) for the power as a function of heritability are given in Figure 1. As shown in 
Figure 1, (1) PE-WS and PE-TOW are consistently more powerful than WS and TOW, 
respectively; (2) PE is the most powerful test when the causal variants contain both 
common and rare variants; and PE is the least powerful test when the causal variants are 
all rare variants; (3) TOW is more powerful than SKAT when the causal variants are all 
rare variants (MAF<0.01) and TOW is less powerful than SKAT when the causal variants 
contain both common and rare variants. The reasons are that (a) TOW and SKAT have 
different weights, otherwise TOW and SKAT are same and (b) the weights of SKAT are 
larger than that of TOW only for those variants with MAF in the range (0.01,0.035), and 
the weights of TOW and SKAT are similar for those variants with MAF>0.035; and (4) 
SKAT-C is less powerful than SKAT when the causal variants are all rare variants 
(MAF<0.01) and SKAT-C is more powerful than SKAT when the causal variants contain 
both common and rare variants. 
 Power comparisons of the seven tests for the power as a function of the percentage of 
protective variants and for the power as a function of the percentage of causal variants 
are given in Figures 2 and 3, respectively. These two figures show that the powers of PE, 
PE-TOW, SKAT, SKAT-C, and TOW are robust to the percentage of protective variants 
and the percentage of causal variants while powers of PE-WS and WS decrease with the 
increasing of the percentage of protective variants and increase with the increasing of the 
percentage of causal variants. Other patterns of power comparisons are similar to that in 
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Figure 1. We also provide power comparisons of the seven tests using a small significance 
level of 10-6 (Figure 4) and using a large sample size of 5000 (Figure 5). Figure 4 shows 
that the patterns of the power comparisons using significance level 10-6 are similar to that 
using a significance level of 0.05 in Figure 1 (Both; Without covariates). Figure 5 shows 
that the patterns of the power comparisons using a sample size of 5000 are similar to that 
using a sample size of 1000 in Figure 1 (Both; Without covariates). 
In summary, PE-WS and PE-TOW are consistently more powerful than WS and TOW, 
respectively. When causal variants contain both common and rare variants, PE is the most 
powerful test, SKAT-C is more powerful than SKAT, and SKAT is more powerful than 
TOW. When causal variants are all rare variants, TOW is more powerful than SKAT, and 
SKAT is more powerful than SKAT-C. The powers of PE, PE-TOW, SKAT, SKAT-C, 
and TOW are robust to the percentage of protective variants and the percentage of causal 
variants. 
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1.5 Analysis of the GAW17 simulated dataset 
The GAW17 simulated dataset consists of a collection of 697 unrelated individuals, their 
real genotypes and 200 replicates of the simulated phenotypes. Three quantitative traits 
Q1, Q2 and Q4 are simulated. Covariates include age, sex, and smoking status. Since 
quantitative trait Q4 has no genetic components, we do not consider Q4 for the purpose 
of power comparisons. We perform power comparisons of the seven tests using 
quantitative traits Q1 and Q2. The p-values of TOW, PE-TOW, PE-WS, and PE are 
evaluated by 10,000 permutations and the p-values of WS, SKAT-C, and SKAT are 
evaluated by asymptotic distributions. The powers of the seven tests are calculated at a 
significance level of 0.001. We merge every two replicates to one replicate to increase 
the sample size. In all cases, the minor allele is associated with higher means of the two 
quantitative traits, which means that all causal variants are risk variants. Q1 has 9 causal 
genes and Q2 has 13 causal genes. We omit causal genes that have one variant, causal 
genes in which all of the seven tests have 100% power, and causal genes in which all of 
the seven tests have a power less than 10%. Q1 has 5 causal genes left and Q2 has 7 causal 
genes left. The powers of TOW, WS, and SKAT to test the association between each of 
the five causal genes and Q1 are not consistent with that in Table 2 of Sha et al. [2012] 
because we found that Sha et al. [2012] did not adjust trait values and genotypes for 
covariates when testing the association for Q1. 
The powers of the seven tests to detect association between each of the 12 causal genes 
and Q1 or Q2 are given in Table 2. As shown in Table 2, WS, TOW, or SKAT-C is the 
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most powerful test in 1 out of 12 genes, PE-WS, PE-TOW, or SKAT is the most powerful 
test in 2 out of 12 genes, and PE is the most powerful test in 4 out of 12 genes. 3 out of 4 
causal genes in which PE or SKAT-C is the most powerful test include common causal 
variants. Causal variants in the 6 genes in which TOW, WS, PE-TOW, or PE-WS is the 
most powerful test are all rare variants (MAF < 1%). Each of the 2 genes in which SKAT 
is the most powerful test contains causal variants with MAF in (0.01,0.035). Comparing 
TOW and WS with PE-TOW and PE-WS, PE-TOW is more powerful than TOW and 
PE-WS is more powerful than WS in 9 out of 12 causal genes. The results from the 
analysis of the GAW17 simulated dataset are consistent with those from the simulation 
studies. 
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1.6 Discussion 
Based on cross-validation prediction error under Ridge regression, we developed novel 
statistical tests to test the association between variants (both common and rare variants) 
in a genomic region and a complex trait of interest. We proposed PE method based on 
Ridge regression. Combined with the weighting schemes, we further developed PE-WS 
and PE-TOW methods. We used extensive simulation studies to compare the 
performance of PE, PE-WS and PE-TOW with that of the existing methods: SKAT, 
SKAT-C, WS, and TOW. Our results showed that (1) the prediction error versions of 
TOW and WS (PE-TOW and PE-WS) are consistently more powerful than TOW and 
WS, respectively; (2) when causal variants contain both common and rare variants, PE is 
the most powerful test, SKAT-C is more powerful than SKAT, and SKAT is more 
powerful than TOW. When causal variants are all rare variants, TOW is more powerful 
than SKAT, and SKAT is more powerful than SKAT-C; and (3) the powers of PE, PE-
TOW, SKAT, SKAT-C, and TOW are robust to the percentage of protective variants and 
the percentage of causal variants. 
Each of the three proposed methods PE, PE-TOW, and PE-WS has its advantages in some 
scenarios. PE is more powerful than PE-TOW and PE-WS when causal variants contain 
both common and rare variants. PE-WS is a burden test and is more powerful than PE-
TOW when the percentage of causal variants is large and the directions of the effects of 
the causal variants are all the same. PE-TOW is more powerful than PE-WS when the 
percentage of causal variants is small or the directions of the effects of the causal variants 
19 
 
are different. We may construct a robust test aiming to have the advantages of all of PE, 
PE-TOW and PE-WS. Let PEp , PE TOWp − , and PE WSp −  denote the P-values of PE, PE-
TOW and PE-WS, respectively. Then, we define the test statistic of the robust test as 
{ }min , ,robust PE PE TOW PE WST p p p− −= . However, the performance of the robust test needs 
further investigation.  
PE test statistic does not work well for rare variants. The reason is that many rare variants 
are singletons. From our simulation results, PE method may be more powerful than 
existing methods for common variants. The performance of PE for common variants 
needs further investigation.  
Among the three proposed tests (PE, PE-WS, and PE-TOW), PE is most computationally 
intensive. The computation time required for running PE depends on the sample size, the 
number of variants in the genomic region, and the number of permutations. The running 
time of PE with 1000 permutations on a data set with 1000 individuals and 100 variants 
in a genomic region on a laptop with 4 Intel Cores @ 3.30GHz and 4 GB memory is about 
0.1s. To perform genome-wide association studies, we can first select genomic regions 
that show evidence of association based on a small number of permutations (e.g. 1,000), 
and then a large number of permutations are used to test the selected regions.   
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1.7 Tables and Figures 
Table 1.1. Type I error rates of the three proposed methods with 10,000 replicates 
 
Significance 
level Sample size 
With covariates Without covariates 
PE-WS PE-TOW PE PE-WS PE-TOW PE 
0.05   
500 0.0545 0.0485 0.0525 0.049 0.0506 0.0504 
1000 0.0503 0.051 0.0519 0.0493 0.0517 0.05 
0.01   
500 0.0104 0.0091 0.0107 0.0099 0.0088 0.0103 
1000 0.0112 0.010 0.0102 0.009 0.0097 0.0103 
0.001   
500 0.0007 0.0009 0.0006 0.0008 0.001 0.0011 
1000 0.0017 0.0005 0.0016 0.0011 0.0009 0.0008 
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Table 1.2. Power of the seven tests to detect the association between each of the five 
causal genes and quantitative trait Q1 and between each of the seven causal genes and 
quantitative trait Q2.  
 
Traits 
Gene 
Name 
No. of 
Variants, 
 No. of 
Causal 
Variants 
Min, Max, 
Mean MAF 
WS TOW PE-WS 
PE-
TOW PE 
SKAT
-C SKAT 
Q1 
ARNT 18, 5 0.07, 1.15, 0.33 0.08 0.52 0.05 0.55 0.83 0.84 0.95 
ELAVL4 10, 2 0.07, 0.07, 0.07 0.44 0.40 0.48 0.53 0.72 0.26 0.00 
FLT4 10, 2 0.07, 0.14, 0.11 0.85 0.68 0.70 0.51 0.79 0.14 0.68 
HIF1A 8, 4 0.07, 1.22, 0.39 0.63 0.56 0.46 0.43 0.91 0.66 0.88 
VEGFA 6, 1 0.22, 0.22, 0.22 0.33 0.16 0.45 0.22 0.22 0.23 0.10 
Q2 
BCHE 29, 13 0.07, 0.29, 0.10 0.20 0.34 0.23 0.38 0.27 0.02 0.14 
LPL 20, 3 0.07, 1.58, 0.60 0.01 0.23 0.05 0.28 0.16 0.33 0.41 
PDGFD 11, 4 0.07, 0.86, 0.29 0.07 0.23 0.09 0.25 0.15 0.04 0.15 
SIRT1 24, 9 0.07, 0.22, 0.12 0.50 0.65 0.52 0.60 0.41 0.61 0.55 
SREBF1 24, 10 0.07, 0.43, 0.22 0.26 0.20 0.27 0.25 0.19 0.03 0.06 
VNN1 7, 2 0.57, 17.1, 8.82 0.06 0.68 0.08 0.78 0.95 0.95 0.02 
VNN3 15, 7 0.07, 9.83, 2.06 0.33 0.55 0.35 0.66 0.73 0.68 0.40 
Note: Min, Max and Mean MAF represent the minimum, maximum, and mean MAF (in 
percentage) at the causal variants. In each row, the boldfaced number represents the 
highest power in the row. 
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Figure 1.1. Power comparisons of the seven tests (PE-WS, PE-TOW, PE, WS, TOW, 
SKAT and SKAT-C) for the power as a function of heritability. “Rare” means that all 
causal variants are rare. “Both” means that causal variants contain both rare and common 
(1 common variant) and the heritability of the common variant is as twice as the 
heritability of all the rare causal variants. x axis represents the total heritability of all 
causal variants. Sample size is 1000. In this set of simulations, all causal variants are risk 
variants and 20% of rare variants are causal. The powers are evaluated at a significance 
level of 0.05. 
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Figure 1.2. Power comparisons of the seven tests (PE-WS, PE-TOW, PE, WS, TOW, 
SKAT and SKAT-C) for the power as a function of the percentage of protective variants. 
“Rare” means that all causal variants are rare. “Both” means that causal variants contain 
both rare and common (1 common variant) and the heritability of the common variant is 
as twice as the heritability of all the rare causal variants. x axis represents the percentage 
of protective variants. Sample size is 1000. The total heritability is 0.03. 20% of rare 
variants are causal. The powers are evaluated at a significance level of 0.05. 
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Figure 1.3. Power comparisons of the seven tests (PE-WS, PE-TOW, PE, WS, TOW, 
SKAT and SKAT-C) for the power as a function of the percentage of causal variants. 
“Rare” means that all causal variants are rare. “Both” means that causal variants contain 
both rare and common (1 common variant) and the heritability of the common variant is 
as twice as the heritability of all the rare causal variants. x axis represents the total 
heritability of all causal variants. Sample size is 1000. The total heritability is 0.03.  All 
causal variants are risk variants. The powers are evaluated at a significance level of 0.05. 
 
 
  
25 
 
Figure 1.4. Power comparisons of the seven tests (PE-WS, PE-TOW, PE, WS, TOW, 
SKAT and SKAT-C) for the power as a function of heritability. “Both” means that causal 
variants contain both rare and common (1 common variant) and the heritability of the 
common variant is as twice as the heritability of all the rare causal variants. x axis 
represents the total heritability of all causal variants. Sample size is 1000. In this set of 
simulations, all causal variants are risk variants and 20% of rare variants are causal. 
Powers are evaluated at significance level 10-6 and p-values of PE-WS, PE-TOW, PE and 
TOW are evaluated by 107 permutations. 
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Figure 1.5. Power comparisons of the seven tests (PE-WS, PE-TOW, PE, WS, TOW, 
SKAT and SKAT-C) for the power as a function of heritability. “Both” means that 
causal variants contain both rare and common (1 common variant) and the heritability 
of the common variant is as twice as the heritability of all the rare causal variants. x axis 
represents the total heritability of all causal variants. Sample size is 5000. In this set of 
simulations, all causal variants are risk variants and 20% of rare variants are causal. The 
powers are evaluated at a significance level of 0.05.
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2 Chapter 2 
Joint Analysis of Multiple Phenotypes in Association Studies based on Cross-
Validation Prediction Error 
In genome-wide association studies (GWAS), the joint analysis of multiple phenotypes 
could have increased power over analyzing each phenotype individually. With this 
motivation, several methods that jointly analyze multiple phenotypes have been 
developed, such as O’Brien’s method, Trait-based Association Test that uses Extended 
Simes procedure (TATES), MAONVA and MultiPhen. However, the performance of 
these methods under a wide range of scenarios is not consistent: one test may be powerful 
in some situations, but not in the others. Thus, one challenge in joint analysis of multiple 
phenotypes is to construct a test that could maintain good performance across different 
scenarios. In this article, we propose a novel statistical method to test the association 
between a genetic variant and multiple phenotypes based on cross-validation prediction 
error (PE). Extensive simulations are conducted to evaluate the type I error rates and to 
compare the power performance of the PE method with various existing methods. We 
show that the PE method controls the type I error rates very well and has consistently 
higher power than the tests we compared in all the scenarios. We conclude with the 
recommendation for the use of the PE method for its high and complementary 
performance. 
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2.1 Introduction 
Traditionally, genome-wide association studies (GWAS) have performed on individual 
phenotype. In spite of the success of GWAS in identifying thousands of associations 
between single nucleotide polymorphism (SNPs) and complex diseases, these identified 
variants only contribute a small portion of the phenotypic variance. In the study of a 
complex disease, several correlated phenotypes are usually measured for a disorder or its 
risk factors [Yang et al., 2010]. Jointly using multiple correlated phenotypes can help to 
increase statistical power to detect causal variants and illuminate on underlying biological 
mechanisms.  
One method to use multiple phenotypes in association study is to perform each phenotype 
separately as standard univariate association test and then aggregate the results, while this 
approach will have a loss in power due to the penalties from the multiple testing [O’Reilly 
et al. 2012; Yang, 2010] and the ignorance of the correlation structure among phenotypes 
[Wang et al. 2015, Yang et al. 2016]. Thus, multiple-phenotype association study that 
uses multiple phenotypes simultaneously has become popular.  
Several methods to detect association using multiple phenotypes have been introduced in 
recent years. For example, O’Brien method (OB) is proposed to combines test statistics 
obtained from association test for each individual phenotype [O’Brien et al. 1984]. OB is 
the most powerful test when the genetic effects are homogeneous, however, this method 
lose power when genetic effects are heterogeneous, especially when genetic effects have 
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opposite directions [Yang et al. 2010; Zhu et al. 2016]. The canonical correlation analysis 
(CCA) proposed by Ferreira & Purcell (2008), conducts the linear combination of 
phenotypes that explain the largest possible amount of the covariation between a genetic 
variant and phenotypes [Ferreira et al. 2008]. We could also use multivariate analysis of 
variance (MANOVA) in regression to study multiple phenotypes [Cole et al., 1994]. 
MANOVA is equivalent to canonical correlation analysis when canonical correlation 
analysis is applied to a single variant [Galesloot et al. 2014]. MultiPhen, which proposed 
by O’Reilly et al. [2012], can be used to detect the association between one SNP and 
multiple phenotypes by reversing response and predictors via a proportional odds 
regression model. And when a small number of phenotypes are included, MultiPhen and 
MANOVA lead to similar performance [Aschard et al. 2014, Zhu et al. 2016]. MANOVA 
and CCA require the assumption of normality of multiple phenotypes, while MultiPhen 
has no inflated type I error rates on non-normal phenotypes. van der Sluis et al. [2013] 
proposed a trait-based association test using an extended Simes procedure (TATES) that 
conducts association test for each phenotype and then combines the univariate p-values 
with corrected correlations among phenotypes [van der Sluis et al. 2013]. Some other 
variable reduction methods have been proposed to test for the association between a 
genetic variant and the linear combination of the multiple phenotypes rather than the 
original phenotypes [Zhu et al., 2018, Wang et al. 2008, Klei et al. 2008]. For example, 
principal component of phenotypes (PCP) that maximizes the phenotype variation, is the 
most popular dimension reduction method [Wang et al. 2008]. Based on PCP, Klei et al. 
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[2008] developed principal component of heritability (PCH) by maximizing the 
heritability among all linear combination of the phenotypes.  
Although there are many proposed methods for joint analysis of multiple phenotypes, the 
performance of these methods under a wide range of scenarios is not consistent [Zhu et 
al. 2016]: one test may be powerful in some situations, but not in the others. Thus, one 
challenge in multiple phenotype analysis is to construct a test that could maintain good 
performance across different scenarios. In this article, we develop a novel statistical 
method to test the association between a genetic variant and multiple phenotypes based 
on cross-validation prediction error (PE). Extensive simulation studies are conducted to 
evaluate the type I error rates and to compare power performance of the PE method with 
various existing methods. We show that the PE method controls the type I error rates very 
well and has consistently higher power than other methods we compared in all the 
scenarios.   
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2.2 Method 
Prediction Error Model 
We consider a sample with n  unrelated individuals. Each individual has K  (potentially 
correlated) phenotypes and has been genotyped at a variant of interest. Let iky  denote 
the thk  phenotype value of the thi  individual and ix  denote the genotype score of the 
thi  
individual, where {0,1,2}ix ∈  is the number of minor alleles that the 
thi  individual 
carries. We model the relationship between the multiple phenotypes and the variant using 
the inverse linear regression model 
0 1 1i K iK iix y yβ β β ε= + + ++ .                                                (1) 
Let ( )11, , ,
T
i i iKy y y…= , 0 1( , , , )
T
Kβ β β β=  and ( )1, , n
Tx x x…= . To test the association 
between the K  multiple phenotypes and the variant, we test the null hypothesis 
10 : 0KH ββ = = =  under equation (1). 
When we conduct analysis on the model, the parameter estimation make the model fit a 
particular dataset as well as possible, it might cause some problems like overfitting. In 
order to have an insight on how generally the model will fit to an independent data and 
how reliably the model will predict future observations, we use cross validation to 
improve the model performance. We apply k-fold cross-validation, divide the data into k 
equal parts, and use each of the k parts as the testing set and other k-1 parts as the training 
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set. We use the training set to estimate β  , and use the prediction equation ˆˆ ii Tyx β=  to 
predict genotypes in the testing set.  
In the k-fold cross-validation, leave-one-out cross-validation (LOOCV) (k is equal to n) 
is an extreme case. LOOCV takes advantage of almost the entire data set, the difference 
between the training set in each fold and the entire dataset is only one single pattern. 
Therefore, LOOCV is approximately unbiased [Luntz et al. 1969]. Also, since each 
sample is used for both training and testing, there is no randomness of allotting some 
samples for training and others for testing, which leads to overall less variability than k-
fold cross-validation method (when k n< ). Furthermore, the LOOCV has a fast 
algorithm to calculate the cross-validation prediction error [James et al. 2013]. In 
conclusion, our proposed test is based on LOOCV. 
We construct a novel statistical test to test the association between the multiple 
phenotypes and the variant in a genomic region based on LOOCV prediction error. We 
propose to use the LOOCV prediction error under model (1) as a test statistic. Let ˆ ix−  
denote the LOOCV predicted value (leave the thi  individual out) of ix  under model (1). 
Then, the statistic can be written as  
 ( )2
1
ˆ
n
i
i
ix xT −
=
= −∑                                                   (2) 
Note that low values of 𝑇𝑇 would imply significance. 
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Parameter estimation 
When the multiple phenotypes are highly correlated with each other, the rank of matrix 
( )1, , n
TY y y…=  will be less than K , then the inverse of TY Y  doesn't exist, which results 
in that the ordinary linear square estimate may not be unique. We can use penalized 
regression, such as Ridge regression [Halawa & Bassiouni, 2000; Hoerl, Kannard, & 
Baldwin, 1975] and Lasso regression [Meier, Van De Geer, & Bühlmann, 2008; 
Tibshirani, 1996; Yuan & Lin, 2006] to make sure that we can find a solution. For 
example, in Ridge regression, we are introducing a diagonal matrix Iλ  along the matrix 
TY Y , which guarantees the matrix TY Y Iλ+  to be invertible. Penalized regressions have 
been applied to the analysis of genetic data [Ayers & Cordell, 2013, 2010; Cule & De 
Iorio, 2013; Cule, Vineis, & De Iorio, 2011; Malo, Libiger, & Schork, 2008; Warren, 
Casas, Hingorani, Dudbridge, & Whittaker, 2014, Yang et al., 2017]. In this paper, we 
propose to use Ridge regression, because another benefit of Ridge regression is reducing 
overfitting through penalizing the size of the regression coefficients and yielding better 
predictions than ordinary linear square estimation via a tradeoff between bias and 
variance.   
In the regression model Ti iix y β ε= + , the ridge regression estimator βˆ  is defined as the 
value of β  that minimizes 2 2( )Ti i j
i j
x y β λ β− +∑ ∑ . The solution to the ridge regression 
problem is given by 1ˆ ( )T TY Y I Y xλβ λ
−= + , where ( )1, , n
TY y y…= , and 0λ ≥  is a tuning 
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parameter. For Ridge regression, let ˆ ixλ−  denote the LOOCV predicted value (leave the thi  
individual out) of ix  under model (1). Then, the statistic can be written as 
( )21 ˆ i
n
ii
xT x λλ −== −∑ .We denote the p-value of Tλ  as pλ . We define the LOOCV 
Prediction Error test statistic (PE) as  
                                minPET pλ λ= .                                                   (3)  
In this study, we use a simple grid search method to evaluate the minimization. We divide 
the interval [0, )∞ into subintervals 1 10 ... L Lλ λ λ−< < <≤ < ∞ . In the simulation studies, 
we used 8L =  and ( ) ( )1 8log , log 0,1,2,3,3.5,4,4, .5,5λ λ =… . Then, 
1min min lPE l LT p pλ λ λ≤ ≤= = .   
We use the same permutation procedure to evaluate the p-value of PET  as in Yang et al. 
[2017]. Intuitively, two layers of permutations are needed to estimate 
l
pλ  and the overall 
p-value for the test statistic PET . Actually, we can use one layer of permutation to estimate 
k
pλ  and the overall p-value for the test statistic PET  [Ge et al., 2003; Yang et al. 2017]. 
Suppose that we perform permutation B times. In each permutation, we randomly shuffle 
the individual genotypes. Let ( )
l
bTλ  denote the values of lTλ  based on the 
thb  permuted 
data for 0,1,...,b B=  and , ,1l L= … , where 0b =  represents the original data. Then, we 
transfer ( )
l
bTλ  to 
( )
l
bpλ  by  
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( )
( ) ( )
( ) : 1, }#{  for ,l k
l
d b
b dp
f b
d T T Bλ λ
λ
…< =
=                                   (4) 
where ( )0f B=  and ( ) 1f b B= −  for , ,1b B= … . Let ( ) ( )1min l
b b
l Lp pλ≤ ≤= . Then, the p-
value of PET  is given by  
( ) (0)#{ :  for 1,2, , }bb p bp B
B
= …< . 
In the next section, we propose an algorithm that can perform the permutation procedure 
described above more efficiently. 
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2.3 A fast algorithm for the permutation procedure 
Let ( )11, ,
T
i i iKy yy …= , ( )1, ,
T
nY y y…= , ( )
1TA Y Y Iλ λ
−
= + , Ti i ih y A yλ λ= , ( )1 ,..., nh h hλ λλ = , 
and ˆ TA Y xλ λβ = . Then, the Ridge predicted values are ˆˆ Ti iyxλ λβ=  and 
( ) ( ) 11ˆ ˆ ˆ,, n
T T TY Y Y Y xx x x Iλ λλ λ
−
= +…= . We can show that LOOCV prediction error in Ridge 
regression has a closed-form formula, that is, ( ) ( )ˆ ˆ 1i i i i ix xx x hλ λ λ−− = − − . For two matrices 
or vectors A  and B , we use A B∗  and A
B
 to denote the element-wise operations. We 
assume 1n K≥ + . We perform singular value decomposition of Y , that is, Y UDV= , 
where U  is an ( )1n K× +  matrix with orthonormal columns, D  is ( ) ( )1 1K K+ × +  
diagonal matrix with non-negative real numbers on the diagonal, and V  is an 
( ) ( )1 1K K+ × +  orthogonal matrix. Let ( )1 1, , KD diag d d +…= . Then, ˆ TUC U xxλ λ= , where 
( ),1 , 1, , KC diag c cλ λ λ +…=  and ( )2 2, j j jc d dλ λ= +  for , 11, Kj … += . Let ( ),1 , 1, , TKcc cλ λ λ +…=  
and ( ) TKx U x=  be a 1K +  dimensional vector. Then, ( ) ( )( )ˆ K Kx UC x U c xλ λ λ= = ∗  and 
( )Th diag UC Uλ λ= . For 10 ... Lλ λ< <≤ < ∞ , let ( )1 , , LcC cλ λ…=  and ( )1 , , LH h hλ λ…= . Then, 
( ) ( )( ) ( ) ( )( )1 1, *ˆ ˆ, ,,L LK K KU C x U cx x cx xλ λ λ λ= = …∗ ∗… . If we denote 
( )1ˆ ˆˆ ,,
1 1
L
x xx
H
X xxB
H
λ λ− −
=
…−
=
− −
, then ( ) ( )1 ,, LT T colSums B Bλ λ… = ∗ . Note that C , U , and 
H  only depend on phenotypes and 1 ,, Lλ λ… . Thus, C , U , and H  do not change in each 
permutation. For a GWAS, C , U , and H also do not change at different SNPs. To 
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perform GWASs, we can first select SNPs that show evidence of association based on a 
small number of permutations (e.g. 1,000), and then a large number of permutations are 
used to test the selected SNPs.  
With the fast algorithm, we can use less than one day to perform a typical GWAS. Our 
preliminary studies showed that performing a GWAS with 5,430 individuals and 7 
phenotypes only needs 10 hours on Intel Xeon E5-2680v3 by using a single node. 
 
2.4 Comparison of Methods 
We compare the performance of the proposed test, PE, with that of the O’Brien’s 
method (OB) [O’Brien et al. 1984], Trait-based Association Test that uses Extended 
Simes procedure (TATES) [van der Sluis et al. 2013], Optimal weight method (OW) 
[Zhu et al., 2016], Multivariate analysis of variance (MANOVA) [Cole et al., 1994], 
and Joint model of multiple phenotypes (MultiPhen)[O’Reilly et al.2012]. 
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2.5 Simulation Study 
In simulation studies, the simulation settings are similar to that of Wang et al. (2016).  
We evaluate Type I error rates of PE method by generating unrelated data sets with three 
different sample sizes, 500, 1,000 and 2,000. For power comparison, we compare powers 
of different methods by simulation data sets with 1,000 unrelated individuals.  
For the genotype data, we generate genotype at one variant by assuming Hardy-Weinberg 
Equilibrium and according to minor allele frequency (MAF). For each individual, we 
generate K  phenotypes ( K = 20 or 40). The K  phenotypes are generated from the 
following model 
                                                  21y cx c ω εφ + += − ×γ                                           (5) 
where 1( ,..., )
T
Ky y y= . 1( ,..., )Kφ φ φ=  are the genetic effects of a variant of interest on 
the K  phenotypes; x  is the genotypic score at the variant; c  is a constant number; γ  is 
a K R×  matrix; 1( ,..., )
T
Rω ω ω=  is a vector of factors with R  elements and 
1( ,..., ) (0, )
T
R MVNω ω ω= Σ , (1 )A Iρ ρΣ = + − , ρ  is the correlation between factors, 
A  is a matrix with elements of 1, and I  is the identity matrix; 1( ,..., )
T
Kε ε ε=  is a vector 
of residuals, 1,..., Kε ε are independent, and ~ (0,1)k Nε  for 1,..., .k K=  Based on 
equation (4), we consider the following four models in which the within-factor correlation 
is 2c  and the between-factor correlation is 2cρ . 
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Model 1: There is only one factor and genotypes impact on all phenotypes with a 
different effect size. That is, 1R = , (1, 2,..., )TKω β= , and (1,...,1)T=γ . 
Model 2: There are two factors and genotypes impact on one factor. That is, 2R = , 
0, ,0, , ,
2
T
K
λ β β
 
 = … … 
 
 
  , and ( )1 2,diag D D=γ , where 1, ,1
2
T
iD
K
 
 =   
 
…  for 1, 2i = . 
Model 3: There are five factors and genotypes impact on two factors. That is, 5R = , 
( )11 1 21 2 31 3 41 4 51 5, , , , ,, , , , , ,, ,,
T
k k k k kλ β β β β β β β β β β= … … … … … , and 
( )1 2 3 4 5, , , ,diag D D DD D=γ , where 
5
,11,
T
i
K
D
 



…= 


 for ,51,i = … ; 5k K= ; 
11 1 21 2 31 3 0k k kβ β β β β β= == = = === =   ; 41 4kβ β β== = − ; and 
( ) ( )51 5
2, 1
1
, , ,k kk
β
β β… = …
+
. 
Model 4: There are five factors and genotypes impact on four factors. That is, 5R = , 
( )11 1 21 2 31 3 41 4 51 5, , , , ,, , , , , ,, ,,
T
k k k k kλ β β β β β β β β β β= … … … … … , and 
( )1 2 3 4 5, , , ,diag D D DD D=γ , where 
5
,11,
T
i
K
D
 



…= 


 for ,51,i = … ; 5k K= ; 11 1 0kβ β== = ; 
21 2kβ β β== = ; 31 3kβ β β== = − ; ( ) ( )41 4
2, 1
1
, , ,k kk
β
β β… = − …
+
; and 
( ) ( )51 5
2, 1
1
, , ,k kk
β
β β… = …
+
. 
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For the Type I error rates, we set 0β =  to indicate that the genetic variant has no effect 
on all phenotypes. For power comparisons, we consider different values of β .  To 
evaluate Type I error rate and power, we set MAF = 0.3, the between-factor correlation 
is 0.15, and the within-factor correlation is 0.25. 
 
2.6 Simulation Result 
To evaluate the Type I error of the proposed PE methods, we consider different 
significance levels (0.01 and 0.05), different sample sizes (500, 1000 and 2000), and 
different number of phenotypes (10, 20 and 40). The p-values of PE are calculated using 
1,000 permutations. Type I error rates are evaluated using 10,000 replicated samples. For 
10,000 replicated samples, the 95% confidence intervals (CIs) for the estimated type I 
error rates of nominal levels 0.05 and 0.01 are (0.04562, 0.05438) and (0.00804, 
0.01196), respectively. The estimated type I error rates of the proposed test are 
summarized in Table 1. From this table, we can see that all of the estimated type I error 
rates are within 95% CIs which indicates that the proposed method is valid. 
In power comparisons, the p-values of PE are calculated using 1,000 permutations, the p-
values of MultiPhen, OW, TATES, MANOVA, OB are evaluated using asymptotic 
distribution. The powers of all of the six tests are evaluated using 1,000 replicated samples 
at a significance level of 0.05.  
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Figures 1 and 2 show the power comparisons of the six methods as a function of effect 
size β  with 20 and 40K = , respectively. As shown in two figures,  
(1) PE is the most powerful method, and the power of PE is much higher than the second 
powerful test. 
(2) as effect size β  increases, the powers of all tests increase as well; as K increases from 
20 to 40, PE presents more ascendancy than the other tests. 
(3) MultiPhen, OW and MANOVA have similar powers under all four models. A similar 
conclusion has been mentioned in some published papers [Zhu et al., 2016, van der 
Sluis et al. 2013, O’Reilly et al.2012]. 
(4) OB is comparable to MultiPhen, OW and MANOVA in model 1 and 2, but has almost 
no power when genetic effects are heterogeneous (model 3 and 4). 
(5) when the genetic variant affects a portion of phenotypes (model 2), TATES is more 
powerful. It is because TATES only depends the strongest associated phenotypes.  
Power comparisons of the six methods as a function of within factor correlation with 
20 and 40K =  are given in Figure 3 and Figure 4, respectively. As shown in these two 
figures,  
(1) PE is the most powerful test. 
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(2) the performance of TATES is relatively robust to the within factor correlation, 
especially when the effects have opposite directions.  
(3) MultiPhen, OW and MANOVA have similar powers under all models. When the 
within factor correlation is increasing, the powers of these three tests have increasing 
trend or decreasing trend depending on the different model settings. This pattern has 
been confirmed in Zhu’s paper [Zhu et al., 2016].   
 
(4) OB is the least powerful test except under model 2 with the within factor correlation 
>0.2.  
In summary, PE is consistently the most powerful test among the tests we compared under 
all simulation scenarios. 
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2.7 Real Data Analysis 
Chronic obstructive pulmonary disease (COPD) is a terminology to describe progressive 
life-threatening lung diseases that causes breathlessness and serious illness, including 
emphysema, chronic bronchitis, refractory asthma and some forms of bronchiectasis. A 
global prevalence of 251 million cases of COPD is reported in 2016 and it is estimated 
that COPD caused 3.17 million deaths in 2015 [WHO, 2017]. The COPDGene aims to 
find inherited or genetic factors that associated with COPD. The COPDGene dataset 
includes 10,192 participants, 3,408 of them are African-Americans(AA), and 6,784 of 
them are non-Hispanic Whites(NHW). We select seven quantitative COPD-related 
phenotypes (FEV1, Emphysema, Emphysema Distribution, Gas Trapping, Airway Wall 
Area, Exacerbation frequency, and Six-minute walk distance) and 4 covariates (BMI, 
Age, Pack-Years and Sex) [Liang et al., 2016] in the following data analysis.  
We deleted individuals and genotypes with missing data. A set of 5,430 non-Hispanic 
Whites across 630, 860 SNPs is used after excluding missing data. Then we adjusted the 
phenotypes for the covariates by apply a linear regression [Sha et al., 2012; Zhu et al., 
2018], we regress each phenotype on covariates, replace original phenotypes with the 
residuals of the regression, and apply each of the six tests to detect the association 
between the covariates-adjusted phenotypes (residuals) and each SNP. 
We use genome-wide significance level 5 × 10−8  to identify SNPs significantly 
associated with the seven COPD-related phenotypes. There are total 14 SNPs identified 
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by at least one method (Table 2). All of the 14 SNPs had been reported to be associated 
with COPD by previous studies [Brehm, et al., 2011; Cho, et al., 2010; Cui, et al., 2014; 
Du, et al., 2016; Hancock, et al., 2010; Li, et al., 2011; Lutz, et al., 2015; Pillai, et al., 
2009; Wilk, et al., 2009; Wilk, et al., 2012; Young, et al., 2010; Zhang, et al., 2011; Zhu, 
et al., 2014].  
As shown in Table 2, MultiPhen identified 14 SNPs; OW, MANOVA and PE identified 
13 SNPs; TATES identified 9 SNPs; and O’Brien method did not identify any SNP. In 
summary, the number of SNPs identified by PE is comparable to the largest number of 
SNPs identified by other tests and the COPD analysis results are consistent with our 
simulation results.  
 
2.8 Discussion  
For complex diseases in GWAS, the association between one SNP and each phenotype is 
usually weak. Analyzing multiple disease-related phenotypes could increase the 
statistical power to identify the association between genotypes and complex diseases. In 
this article, we developed a novel statistical method, PE, to test the association between 
a genetic variant and multiple phenotypes based on cross-validation prediction error, and 
showed that the PE method controls the type I error rates very well and has consistently 
high power among all the scenarios. Overall, PE is the most powerful test and has much 
higher power than the second powerful test; OW, MANOVA, and MultiPhen have very 
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similar performance; OB loses power dramatically when genetics effects are 
heterogeneous, especially when opposite effect directions occur; TATES is relatively 
robust to within factor correlation and more powerful when the genetic effect only works 
on a portion of phenotypes. In real data analysis, PE identified 13 out of 14 significant 
SNPs, which is comparable to MultiPhen (14 out of 14). 
In COPDGene study, we incorporated covariates by regressing the phenotypes on 
covariates and considered the residuals as adjusted phenotypes [Sha et al., 2012; Zhu et 
al., 2018]. And we removed the observations with any missing information. For COPD 
dataset, the missing rate is about 20%. Note that deletion of missing data results in the 
reducing of sample size which leads to loss of power. In real data analysis, if the missing 
rate is more than 30%, we can use imputation methods [Ali et al., 2011] to impute missing 
data.    
In summary, we believe that PE is a recommended approach since it provided robust good 
performance to test multiple phenotypes with a genetic variant under different scenarios.  
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2.9 Tables and Figures 
Table 2.1. Estimated Type I error rates for the PE method under four models. The Type 
I error rates are evaluated using 10,000 replicated samples. P-values of PE are estimated 
by 1,000 permutations. α  is the significance level. For 10,000 replicated samples, the 
95% confidence intervals (CIs) for Type I error rates at nominal levels 0.05 and 0.01 are 
(0.04562, 0.05438) and (0.00804, 0.01196), respectively. 
 
Sample 
Size 
Number of 
Phenotypes 
Significance 
Level Model 1 Model 2 Model 3 Model 4 
 
 
 
 
500 
 
10 
0.01α =  0.0103 0.0109 0.0112 0.0094 
0.05α =  0.0480 0.0512 0.0523 0.0532 
 
20 
0.01α =  0.0116 0.0107 0.0114 0.0112 
0.05α =  0.0503 0.0499 0.0473 0.0515 
 
40 
0.01α =  0.0112 0.0118 0.0121 0.0103 
0.05α =  0.0524 0.0515 0.0518 0.0541 
 
 
 
 
1000 
 
10 
0.01α =  0.0503 0.0499 0.0473 0.0479 
0.05α =  0.0535 0.0532 0.0514 0.0492 
 
20 
0.01α =  0.0101 0.0095 0.0112 0.0083 
0.05α =  0.0500 0.0501 0.0524 0.0469 
 
40 
0.01α =  0.0094 0.0116 0.0117 0.0105 
0.05α =  0.0472 0.0512 0.0514 0.0508 
 
 
 
 
2000 
 
10 
0.01α =  0.0111 0.0094 0.0118 0.0094 
0.05α =  0.0489 0.0491 0.0508 0.0465 
 
20 
0.01α =  0.0113 0.0107 0.0098 0.0108 
0.05α =  0.0513 0.0491 0.0516 0.0523 
 
40 
0.01α =  0.0099 0.0091 0.0107 0.0110 
0.05α =  0.0498 0.0480 0.0492 0.0476 
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Table 2.2 Significant SNPs and the corresponding p-values in the analysis of 
COPDGene. The p-values of PE are evaluated using 108 permutations The p-values of 
OB, TATES, OW, MANOVA, and MultiPhen are evaluated using asymptotic 
distributions. The graying out p-values indicate the p-values >  5 × 10−8. 
 
Chr Position Variant identifier OB TATES OW MANOVA MultiPhen PE 
4 145431497 rs1512282 0.46 7.09 × 10−13 8.10 × 10−14 6.52 × 10−14 1.03 × 10−9 0 
4 145434744 rs1032297 0.49 0 1.11 × 10−16 1.11 × 10−16 7.69 × 10−14 0 
4 145474473 rs1489759 0.42 0 1.11 × 10−16 6.68 × 10−17 1.22 × 10−16 1.00 × 10−8 
4 145485738 rs1980057 0.49 0 1.11 × 10−16 7.12 × 10−17 8.14 × 10−17 1.00 × 10−8 
4 145485915 rs7655625 0.34 6.11 × 10−9 1.87 × 10−9 1.69 × 10−9 9.13 × 10−17 5.00 × 10−8 
15 78882925 rs16969968 0.96 5.40 × 10−8 2.05 × 10−11 1.77 × 10−11 7.84 × 10−12 0 
15 78894339 rs1051730 0.99 3.13 × 10−8  1.54 × 10−11 1.32 × 10−11 8.16 × 10−12 0 
15 78898723 rs12914385 0.99 2.76 × 10−8 1.64 × 10−11 1.41 × 10−11 1.48 × 10−12 0 
15 78911181 rs8040868 0.99 5.53 × 10−10 2.09 × 10−12 1.76 × 10−12 2.59 × 10−12 0 
15 78878541 rs951266 0.77 2.55 × 10−9 3.24 × 10−12 2.74 × 10−12 1.02 × 10−11 0 
15 78806023 rs8034191 0.87 1.06 × 10−7 2.42 × 10−10 2.14 × 10−10 7.74 × 10−11 0 
15 78851615 rs2036527 0.88 1.62 × 10−7 4.47 × 10−10 3.99 × 10−10 1.77 × 10−10 0 
15 78826180 rs931794 0.91 1.23 × 10−7 2.64 × 10−10 2.35 × 10−10 9.09 × 10−11 0 
15 78740964 rs2568494 0.27 2.93 × 10−5 1.12 × 10−7 1.05 × 10−7 4.23 × 10−8 1.50 × 10−7 
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Figure 2.1 Power comparisons of the six methods as a function of effect size β . The total 
number of phenotypes is 20K = , sample size is 1000, MAF is 0.3, the between-factor 
correlation is 0.15, and the within-factor correlation is 0.25. Significance is assessed at 
the 5% level. 
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Figure 2.2. Power comparisons of the six methods as a function of effect size β . The 
total number of phenotypes is 40K = , sample size is 1000, MAF is 0.3, the between-
factor correlation is 0.15, and the within-factor correlation is 0.25. Significance is 
assessed at the 5% level.  
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Figure 2.3 Power comparisons of the six methods as a function of within factor 
correlation. The total number of phenotypes is 20K = , sample size is 1000, MAF is 0.3, 
the between-factor correlation is 0.15. Significance is assessed at the 5% level. 
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Figure 2.4 Power comparisons of the six methods as a function of within factor 
correlation. The total number of phenotypes is 40K = , sample size is 1000, MAF is 0.3, 
the between-factor correlation is 0.15. Significance is assessed at the 5% level. 
 
 
 
 
52 
 
3 Reference List 
 
Ahituv, N., et al. (2007). "Medical Sequencing at the Extremes of Human Body Mass." 
The American Journal of Human Genetics 80(4): 779-791. 
Ali, A., et al. (2011). "Comparison of methods for handling missing data on 
immunohistochemical markers in survival analysis of breast cancer." British 
journal of cancer 104(4): 693. 
Allen, H. L., et al. (2010). "Hundreds of variants clustered in genomic loci and biological 
pathways affect human height." Nature 467(7317): 832. 
Andrés, A. M., et al. (2007). "Understanding the accuracy of statistical haplotype 
inference with sequence data of known phase." Genetic epidemiology 31(7): 659-
671. 
Aschard, H., et al. (2014). "Maximizing the power of principal-component analysis of 
correlated phenotypes in genome-wide association studies." The American 
Journal of Human Genetics 94(5): 662-676. 
Ayers, K. L. and H. J. Cordell (2010). "SNP selection in genome‐wide and candidate gene 
studies via penalized logistic regression." Genetic epidemiology 34(8): 879-891. 
Ayers, K. L. and H. J. Cordell (2013). "Identification of grouped rare and common 
variants via penalized logistic regression." Genetic epidemiology 37(6): 592-602. 
53 
 
Bodmer, W. and C. Bonilla (2008). "Common and rare variants in multifactorial 
susceptibility to common diseases." Nature genetics 40(6): 695. 
Brehm, J. M., et al. (2011). "Identification of FGF7 as a novel susceptibility locus for 
chronic obstructive pulmonary disease." Thorax 66(12): 1085-1090. 
Cho, M. H., et al. (2010). "Variants in FAM13A are associated with chronic obstructive 
pulmonary disease." Nature genetics 42(3): 200. 
Cohen, J. C., et al. (2004). "Multiple rare alleles contribute to low plasma levels of HDL 
cholesterol." Science 305(5685): 869-872. 
Cohen, J. C., et al. (2006). "Multiple rare variants in NPC1L1 associated with reduced 
sterol absorption and plasma low-density lipoprotein levels." Proceedings of the 
National Academy of Sciences of the United States of America 103(6): 1810-
1815. 
Cole, D. A., et al. (1994). "How the power of MANOVA can both increase and decrease 
as a function of the intercorrelations among the dependent variables." 
Psychological Bulletin 115(3): 465. 
Consortium, U. K. (2015). "The UK10K project identifies rare variants in health and 
disease." Nature 526(7571): 82. 
Chronic obstructive pulmonary disease (COPD). WHO. November 2017. Retrieved 
from http://www.who.int/mediacentre/factsheets/fs315/en/ 
54 
 
Cui, K., et al. (2014). "Four SNPs in the CHRNA3/5 alpha-neuronal nicotinic 
acetylcholine receptor subunit locus are associated with COPD risk based on 
meta-analyses." PloS one 9(7): e102324. 
Cule, E. and M. De Iorio (2013). "Ridge regression in prediction problems: automatic 
choice of the ridge parameter." Genetic epidemiology 37(7): 704-714. 
Cule, E., et al. (2011). "Significance testing in ridge regression for genetic data." BMC 
bioinformatics 12(1): 372. 
De, G., et al. (2013). "Rare variant analysis for family-based design." PloS one 8(1): 
e48495. 
Derkach, A., et al. (2013). "Robust and powerful tests for rare variants using Fisher's 
method to combine evidence of association from two or more complementary 
tests." Genetic epidemiology 37(1): 110-121. 
Du, Y., et al. (2016). "Association of IREB2 gene rs2568494 polymorphism with risk of 
chronic obstructive pulmonary disease: a meta-analysis." Medical science 
monitor: international medical journal of experimental and clinical research 22: 
177. 
Feng, S., et al. (2015). "Methods for Association Analysis and Meta‐Analysis of Rare 
Variants in Families." Genetic epidemiology 39(4): 227-238. 
55 
 
Ferreira, M. A. and S. M. Purcell (2008). "A multivariate test of association." 
Bioinformatics 25(1): 132-133. 
Gavish, B., et al. (2008). "Linear relationship between systolic and diastolic blood 
pressure monitored over 24 h: assessment and correlates." Journal of hypertension 
26(2): 199-209. 
Ge, Y., et al. (2003). "Resampling-based multiple testing for microarray data analysis." 
Test 12(1): 1-77. 
Greco, B., et al. (2016). "A general approach for combining diverse rare variant 
association tests provides improved robustness across a wider range of genetic 
architectures." European Journal of Human Genetics 24(5): 767. 
Halawa, A. and M. El Bassiouni (2000). "Tests of regression coefficients under ridge 
regression models." Journal of Statistical Computation and Simulation 65(1-4): 
341-356. 
Han, F. and W. Pan (2010). "A data-adaptive sum test for disease association with 
multiple common or rare variants." Human heredity 70(1): 42-54. 
Hancock, D. B., et al. (2010). "Meta-analyses of genome-wide association studies 
identify multiple loci associated with pulmonary function." Nature genetics 42(1): 
45. 
56 
 
Hodges, E., et al. (2007). "Genome-wide in situ exon capture for selective resequencing." 
Nature genetics 39(12): 1522. 
Hoerl, A. E., et al. (1975). "Ridge regression: some simulations." Communications in 
Statistics-Theory and Methods 4(2): 105-123. 
Hoffmann, T. J., et al. (2010). "Comprehensive approach to analyzing rare genetic 
variants." PloS one 5(11): e13584. 
Huang, J., et al. (2015). "Improved imputation of low-frequency and rare variants using 
the UK10K haplotype reference panel." Nature communications 6: 8111. 
Ionita-Laza, I., et al. (2013). "Sequence kernel association tests for the combined effect 
of rare and common variants." The American Journal of Human Genetics 92(6): 
841-853. 
James, G., et al. (2013). An introduction to statistical learning, Springer. 
Ji, W., et al. (2008). "Rare independent mutations in renal salt handling genes contribute 
to blood pressure variation." Nature genetics 40(5): 592. 
Kim, J., et al. (2015). "An adaptive association test for multiple phenotypes with GWAS 
summary statistics." Genetic epidemiology 39(8): 651-663. 
Klei, L., et al. (2008). "Pleiotropy and principal components of heritability combine to 
increase power for association analysis." Genetic epidemiology 32(1): 9-19. 
57 
 
Lange, L. A., et al. (2014). "Whole-exome sequencing identifies rare and low-frequency 
coding variants associated with LDL cholesterol." The American Journal of 
Human Genetics 94(2): 233-245. 
Lee, S., et al. (2012). "Optimal unified approach for rare-variant association testing with 
application to small-sample case-control whole-exome sequencing studies." The 
American Journal of Human Genetics 91(2): 224-237. 
Li, B. and S. M. Leal (2008). "Methods for detecting associations with rare variants for 
common diseases: application to analysis of sequence data." The American 
Journal of Human Genetics 83(3): 311-321. 
Li, X., et al. (2011). "Importance of hedgehog interacting protein and other lung function 
genes in asthma." Journal of Allergy and Clinical Immunology 127(6): 1457-
1465. 
Liang, X., et al. (2016). "An Adaptive Fisher’s Combination Method for Joint Analysis 
of Multiple Phenotypes in Association Studies." Scientific Reports 6: 34323. 
Lin, D.-Y. and Z.-Z. Tang (2011). "A general framework for detecting disease 
associations with rare variants in sequencing studies." The American Journal of 
Human Genetics 89(3): 354-367. 
Locke, D. E., et al. (2006). "Relationship of indicators of neuropathology, 
psychopathology, and effort to neuropsychological results in patients with 
58 
 
epilepsy or psychogenic non-epileptic seizures." Journal of clinical and 
experimental neuropsychology 28(3): 325-340. 
Luntz, A. (1969). "On estimation of characters obtained in statistical procedure of 
recognition." Technicheskaya Kibernetica 3. 
Lutz, S. M., et al. (2015). "A genome-wide association study identifies risk loci for 
spirometric measures among smokers of European and African ancestry." BMC 
genetics 16(1): 138. 
Madsen, B. E. and S. R. Browning (2009). "A groupwise association test for rare 
mutations using a weighted sum statistic." PLoS genetics 5(2): e1000384. 
Malo, N., et al. (2008). "Accommodating linkage disequilibrium in genetic-association 
analyses via ridge regression." The American Journal of Human Genetics 82(2): 
375-385. 
Manolio, T. A., et al. (2009). "Finding the missing heritability of complex diseases." 
Nature 461(7265): 747. 
Marini, N. J., et al. (2008). "The prevalence of folate-remedial MTHFR enzyme variants 
in humans." Proceedings of the National Academy of Sciences 105(23): 8055-
8060. 
McCarthy, M. I., et al. (2008). "Genome-wide association studies for complex traits: 
consensus, uncertainty and challenges." Nature reviews genetics 9(5): 356. 
59 
 
Meier, L., et al. (2008). "The group lasso for logistic regression." Journal of the Royal 
Statistical Society: Series B (Statistical Methodology) 70(1): 53-71. 
Morgenthaler, S. and W. G. Thilly (2007). "A strategy to discover genes that carry multi-
allelic or mono-allelic risk for common diseases: a cohort allelic sums test 
(CAST)." Mutation Research/Fundamental and Molecular Mechanisms of 
Mutagenesis 615(1): 28-56. 
Ng, S. B., et al. (2009). "Targeted capture and massively parallel sequencing of 12 human 
exomes." Nature 461(7261): 272. 
O'Brien, P. C. (1984). "Procedures for comparing samples with multiple endpoints." 
Biometrics: 1079-1087. 
O’Reilly, P. F., et al. (2012). "MultiPhen: joint model of multiple phenotypes can increase 
discovery in GWAS." PloS one 7(5): e34861. 
Pillai, S. G., et al. (2009). "A genome-wide association study in chronic obstructive 
pulmonary disease (COPD): identification of two major susceptibility loci." PLoS 
genetics 5(3): e1000421. 
Price, A. L., et al. (2010). "Pooled association tests for rare variants in exon-resequencing 
studies." The American Journal of Human Genetics 86(6): 832-838. 
Price, A. L., et al. (2006). "Principal components analysis corrects for stratification in 
genome-wide association studies." Nature genetics 38(8): 904. 
60 
 
Pritchard, J. K. (2001). "Are rare variants responsible for susceptibility to complex 
diseases?" The American Journal of Human Genetics 69(1): 124-137. 
Pritchard, J. K. and N. J. Cox (2002). "The allelic architecture of human disease genes: 
common disease–common variant… or not?" Human molecular genetics 11(20): 
2417-2423. 
Ray, D., et al. (2016). "USAT: A Unified Score‐Based Association Test for Multiple 
Phenotype‐Genotype Analysis." Genetic epidemiology 40(1): 20-34. 
Romeo, S., et al. (2007). "Population-based resequencing of ANGPTL4 uncovers 
variations that reduce triglycerides and increase HDL." Nature genetics 39(4): 
513. 
Romeo, S., et al. (2009). "Rare loss-of-function mutations in ANGPTL family members 
contribute to plasma triglyceride levels in humans." The Journal of clinical 
investigation 119(1): 70-79. 
Sha, Q., et al. (2013). "Adaptive clustering and adaptive weighting methods to detect 
disease associated rare variants." European Journal of Human Genetics 21(3): 
332. 
Sha, Q., et al. (2012). "Detecting association of rare and common variants by testing an 
optimally weighted combination of variants." Genetic epidemiology 36(6): 561-
571. 
61 
 
Sha, Q. and S. Zhang (2014). "A Rare Variant Association Test Based on Combinations 
of Single‐Variant Tests." Genetic epidemiology 38(6): 494-501. 
Shen, L., et al. (2010). "Whole genome association study of brain-wide imaging 
phenotypes for identifying quantitative trait loci in MCI and AD: A study of the 
ADNI cohort." Neuroimage 53(3): 1051-1063. 
Stratton, M. R. and N. Rahman (2008). "The emerging landscape of breast cancer 
susceptibility." Nature genetics 40(1): 17. 
Sun, J., et al. (2016). "A method for analyzing multiple continuous phenotypes in rare 
variant association studies allowing for flexible correlations in variant effects." 
European Journal of Human Genetics 24(9): 1344. 
Taylor, P. N., et al. (2015). "Whole-genome sequence-based analysis of thyroid function." 
Nature communications 6: 5681. 
Teer, J. K. and J. C. Mullikin (2010). "Exome sequencing: the sweet spot before whole 
genomes." Human molecular genetics 19(R2): R145-R151. 
Tibshirani, R. (1996). "Regression shrinkage and selection via the lasso." Journal of the 
Royal Statistical Society. Series B (Methodological): 267-288. 
Van der Sluis, S., et al. (2013). "TATES: efficient multivariate genotype-phenotype 
analysis for genome-wide association studies." PLoS genetics 9(1): e1003235. 
62 
 
Walsh, T. and M.-C. King (2007). "Ten genes for inherited breast cancer." Cancer cell 
11(2): 103-105. 
Wang, Y., et al. (2015). "Pleiotropy analysis of quantitative traits at gene level by 
multivariate functional linear models." Genetic epidemiology 39(4): 259-275. 
Wang, Z., et al. (2016). "Joint analysis of multiple traits using" optimal" maximum 
heritability test." PloS one 11(3): e0150975. 
Warren, H., et al. (2014). "Genetic prediction of quantitative lipid traits: comparing 
shrinkage models to gene scores." Genetic epidemiology 38(1): 72-83. 
Wilk, J. B., et al. (2009). "A genome-wide association study of pulmonary function 
measures in the Framingham Heart Study." PLoS genetics 5(3): e1000429. 
Wilk, J. B., et al. (2012). "Genome-wide association studies identify CHRNA5/3 and 
HTR4 in the development of airflow obstruction." American journal of respiratory 
and critical care medicine 186(7): 622-632. 
Wu, B. and J. S. Pankow (2016). "Sequence kernel association test of multiple continuous 
phenotypes." Genetic epidemiology 40(2): 91-100. 
Wu, M. C., et al. (2011). "Rare-variant association testing for sequencing data with the 
sequence kernel association test." The American Journal of Human Genetics 
89(1): 82-93. 
63 
 
Yang, J. J., et al. (2016). "An efficient genome-wide association test for multivariate 
phenotypes based on the Fisher combination function." BMC bioinformatics 
17(1): 19. 
Yang, Q., et al. (2010). "Analyze multivariate phenotypes in genetic association studies 
by combining univariate association tests." Genetic epidemiology 34(5): 444-454. 
Yang, X., et al. (2017). "Detecting association of rare and common variants based on 
cross‐validation prediction error." Genetic epidemiology 41(3): 233-243. 
Yi, N. and D. Zhi (2011). "Bayesian analysis of rare variants in genetic association 
studies." Genetic epidemiology 35(1): 57-69. 
Young, R., et al. (2010). "Chromosome 4q31 locus in COPD is also associated with lung 
cancer." European Respiratory Journal 36(6): 1375-1382. 
Yuan, M. and Y. Lin (2006). "Model selection and estimation in regression with grouped 
variables." Journal of the Royal Statistical Society: Series B (Statistical 
Methodology) 68(1): 49-67. 
Zhang, J., et al. (2011). "Nicotinic acetylcholine receptor variants associated with 
susceptibility to chronic obstructive pulmonary disease: a meta-analysis." 
Respiratory research 12(1): 158. 
Zheng, H. F., et al. (2015). "Whole‐genome sequencing identifies EN1 as a determinant 
of bone density and fracture." Nature 526(7571): 112. 
64 
 
Zhu, A. Z., et al. (2014). "Association of CHRNA5‐A3‐B4 SNP rs2036527 With 
Smoking Cessation Therapy Response in African‐American Smokers." Clinical 
Pharmacology & Therapeutics 96(2): 256-265. 
Zhu, H., et al. (2015). "Power comparisons of methods for joint association analysis of 
multiple phenotypes." Human heredity 80(3): 144-152. 
Zhu, H., et al. (2018). "A novel method to test associations between a weighted 
combination of phenotypes and genetic variants." PloS one 13(1): e0190788. 
Zhu, X., et al. (2010). "Detecting rare variants for complex traits using family and 
unrelated data." Genetic epidemiology 34(2): 171-187. 
 
  
65 
 
Appendix A: The closed-form formula of cross-
validation prediction error of LOOCV for Ridge 
regression 
Let ( )11, ,
T
i i iMx gg …=  and ( )1, ,
T
nX x x…= . Let ( )
1TA X X Iλ λ
−
= + , Ti i ih x A x
λ
λ= , and 
ˆ TA X yλ λβ = . Let ˆˆ
T
i ixy
λ
λβ=  and 
TB XA Xλ λ= , then ( ) ( )1 ,..., nh h h diag Bλ λλ λ= = . Let 
iX − , ,ˆ iλβ − , and ˆciy
λ  denote X , ˆλβ , and ˆiy
λ  when the thi  individual leaves out. Noting 
that T T Ti i i iX X X X x x− − = − , then we have  
( ) 1, T Ti i iA X X xI xλ λ
−
− = + −  
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A x x A
A x
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xλ λ λλ
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−
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i i i i
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x A X y x yλ λ λλ
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Therefore, ( )1ˆ 1 ˆi ci i ii
y y y
h
yλ λλ− = −−
. 
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Appendix B: The fast algorithms for permutation 
procedures 
1) PE method  
We use the same notations as in Appendix A. Let ( )1 ,ˆ ˆ ˆ, n
T
y y yλ λλ …=  and then 
( ) 1ˆ T TX X X yy XIλ λ
−
= + . For two matrices or vectors A  and B , we use A B∗  and 
A
B
 to denote the element-wise operations. Let m  denote the number of columns of 
matrix X . We assume n m≥ . We perform singular value decomposition of X , that is, 
X UDV= , where U  is an n m×  matrix with orthonormal columns, D  is m m×  
diagonal matrix with non-negative real numbers on the diagonal, and V  is an m m×  
orthogonal matrix. Let ( )1 ,, mD diag d d…= . Then, ˆ TUC U yyλ λ= , where 
( ),1 ,, , mC diag ccλ λ λ…=  and 
2
, 2
j
j
j
d
c
dλ λ
=
+
 for , ,1j m= … . Let ( ),1 ,, ,
T
mcc cλ λ λ…=  and 
( ) Tmy U y=  be a m  dimensional vector. Then, ( ) ( )( )ˆ m my UC y U c yλ λ λ= = ∗  and 
( )Th diag UC Uλ λ=  (in R code, ( )( )( )h rowSums U t t U cλ λ= ∗ ∗ ). For 
1 10 ... K Kλ λ λ−< < <≤ < ∞ , let ( )1 , , KcC cλ λ…=  and ( )1 , , KH h hλ λ…= . Then, 
( ) ( )( ) ( ) ( )( )1 1, *ˆ ˆ, ,, KK m m mU C y U cy y cy yλ λ λ λ= = …∗ ∗… . If we denote 
( )1ˆ ˆ,,
1
K
y y
B
H
y yλ λ− −
=
−
…
, then ( ) ( )1 ,, KT T colSums B Bλ λ… = ∗ . Note that C , U , and H  
do not change in each permutation.  
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2) PE-TOW and PE-WS methods 
For PE-TOW, let ( )1, , n
TX x x…= , where i ix GG= − . We first centralize the trait 
values y . For simplicity, we still use ( )1, ,
T
ny y y…=  to denote the trait values after 
centralization. Let 2
1
T
i
n
i
d X X x
=
= =∑ , 1T i i
n
i
Y X y x y
=
= =∑ , and 
1c
dλ λ
=
+
. Then, 
yˆ Yc Xλ λ=  and 
2
iih c x
λ
λ= . Note that we need to recalculate X  in each permutation. 
For PE-WS, the same formulas for PE-TOW are applied. However, X  does not change 
in each permutation. 
 
